2005, Number S3
<< Back Next >>
Arch Cardiol Mex 2005; 75 (S3)
The centennial of blood coagulation doctrine
Izaguirre ÁR
Language: Spanish
References: 61
Page: 118-129
PDF size: 181.00 Kb.
ABSTRACT
For centuries, the mystery surrounding blood coagulation stimulated the curiosity of researchers. The knowledge about this function has increased notably in the last century and has permitted to understand numerous physiopatho logical phenomena in several hemorrhagic and thrombotic diseases, and has made it possible to develop diverse drugs of proved efficacy for prevention and therapy. All this was initiated in 1905, when Paul Morawitz published an extensive monograph on the four factors of blood coagulation known until then (fibrinogen, thrombin, thrombokinase, and calcium). In that work, he proposed a blood coagulation model in two stages: thrombin generation and fibrinogen coagulation. In the 1940s a true golden age in coagulation was started with the results of Quick’s prothrombin time test, described in 1936, and since then the most employed coagulation test. Besides numerous factors involved in this function were discovered and classified. The discovery and introduction of heparin and coumarin in the anticoagulant therapeutics opened a measureless panorama for the arrival of new antithrombotic drugs. By the middle of the XX century, the mechanism of coagulation had been practically deciphered and diverse models based on sequential enzymatic function were proposed, called first
chain reactions and
in cascade reactions later. In the second half of the XX century, numerous regulatory mechanisms of coagulation were identified and diverse laboratory tests appeared that have allowed highly precise diagnoses of a variety of diseases. Blood separation techniques have permitted to produce factor concentrates for clinical use. With the identification of the genes that encode the synthesis of coagulation factors, it has been possible to produce them by means of molecular biology techniques, being the most significant the production of factors VIII, IX, and VII. The present model of coagulation is based on tissular factor activation and the participation of cells, concepts that were already implicit in the classical theory of Morawitz.
REFERENCES
Morawitz P: Beiträge zur kenntnis der blutgerinnung. Beitr Chem Physiol Pathol 1904; 5: 133-141.
Morawitz P: Beiträge zur kenntnis der blutgerinnung. 2 Mitteilung. Deutsche Arch Klin Med 1904; 79: 215-233.
Morawitz P: Die Chemie der Blutgerinnung. Ergebn Physiol 1905; 4: 307-423.
Quick A: Hemorrhagic diseases and thrombosis. Philadelphia. Lea & Febiger. 1966: 15-33.
Malpighi M: De viscerum structura exercitatio anatomica. Accedit dissertatio eiusdem de Polypo Cordis. Bolonia, Iacobo Monti, 1666.
Forge E: Histoire de la Chirurgie. En: Lavastine L. Ed. Histoire Genérale de la Médecine, de la Pharmacie, de l’art dentaire et de l’art vétérinaire. París. Albin Michel Editeurs, 1936; 2: 351.
Buchanan A: Contributions to the physiology and pathology of the animal fluids. London Med Gaz 1836; 18: 50-54.
Buchanan A: On the coagulation of the blood and other fibriniferous liquids. J Physiol 1879; 2: 158-163. Reimpreso de : London Med Gaz o J Pract Med 1845; 1: 617.
Schmidt A: Ueber den faserstoff und die ursachen seiner gerinnung. Reichert DuBois Reymond´s P. Arch Anat Physiol 1861: 545-587, 675-721.
Schmidt A: Weiteres über den faserstoff und die ursachen seiner gerinnung. Arch Anat Physiol 1862: 428-469.
Arthus M: La coagulation du sang et les sels de chaux (rèfutation experimentale des objections d´Alexander Schmidt). Arch Physiol 1896; 8: 47-61.
Wintrobe M: Hematology, the bloosoming of a science: a story of inspiration and effort. Philadelphia: Lea & Fabiger, 1985: 102-103.
Fuld E, Spiro K: Der Einfluss einige gerinnungshemmender Agienten auf das Vogelplasma. Hofmeisters Beitr Chem Physiol Pathol 1904: 171-190.
Arthus M. Précis de Physiologie. París: Masson & Cie Éditeurs, 1912: 32-37.
Douris R. Guide practique pour l´Analyse dun sang. Paris: Vigot Fréres, Éditeurs, 1925:18-28.
Howell Wh: A text-book of Physiology. 2a. Ed. Philadelphia: W.A. Saunders Company, 1908: 426-436.
McLean J: The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-257.
Howell WH: A textbook of Physiology. 7ma. Ed. Philadelphia: WA. Saunders Company, 1919: 453-469.
Howell WH: Theories of blood clotting. Physiol Rev 1935;15: 435-470.
Beck R. Laboratory Manual of Hematologic Technic. Philadelphia: W.B. Saunders Company, 1938: 30-43.
Jaques B: The Howell theory of blood coagulation: a record of the pernicious effects of a false theory. Can Bull Med His 1988; 5: 143-165.
Dam H: Vitamin K, its chemistry and physiology. Adv Enzymol 1942; 2: 285-324.
Doisy EA, Binkley SB, Thayer SA: Vitamin K. Chem Rev 1941; 28: 477-517.
Link KP: The discovery of dicumarol and its sequels. Circulation 1997; 19: 97-107.
Quick A, Stanley-Brown M, Bancroft FW: A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 501-511.
Patek AJ, Taylor FHL: Hemophilia II. Some proprieties of a substance obtained from normal plasma effective in accelerating the clotting of hemophiliac blood. J Clin Invest 1937; 16: 113-124.
Pavlovsky A: Contribution to the pathogenesis of hemophilia. Blood 1947; 2: 185-191.
Biggs R, Douglas A: The thromboplastin generation test. J Clin Pathol 1953; 6: 23-29.
Biggs R, Douglas A, MacFarlane R: Christmas disease. A condition previously mistaken for haemophilia. BMJ 1952; 2: 1378-1382.
Izaguirre R: Historia de la Hemofilia. En: Martínez, C. Ed: Hemofilia. México: Editorial Prado, 2001: 1-17.
Fischer A: Coagulation of the blood as a chain-reaction. Nature 1935; 1075: 135.
Milstone JH: The chain reaction of the blood clotting mechanism in relation to the theory of hemostasis and thrombosis. Blood 1949; 4: 1290-1297.
Milsone JH: Evolution of blood clotting theory. Medicine 1952; 31: 411- 447.
Davie EW, Ratnoff OD: Waterfall sequence for intrinsec blood clotting. Science 1964; 145: 1310-1312.
MacFarlane RG: An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 1964; 202: 498-499.
Nygaard K, Brown G: Essential thrombophilia. Report of five cases. Arch Int Med 1937; 59: 82-106.
Ulutin ON, Seegers WH: Autoprothrombin II and Autoprothrombin II anticoagulant. Thromb Diath Haemorrh 1962; 7(S): 256-263.
Esmon CT, Taylor FB, Snow TR: Inflammation and coagulation. Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66: 160-165.
Nemerson Y: Tissue factor and hemostasis. Blood 1988; 71: 1-8.
Bach RR: Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988; 23: 339-368.
Camerer E, Kolsto AB, Pryds H: Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
Morrissey JH: Tissue factor and factor VII initiation of coagulation. En: Colman RW, Hirsh J, Marder VJ, et al. Eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams & Wilkins, 2001: 89-101.
Hoffman M, Monroe DM: A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
Brummel-Ziedins K, Orfeo T, Swords J, et al: Blood coagulation and fibrinolysis. En: Greer J, Foerster J, Lukens J, et al. Wintrobe´s Clinical Hematology. Philadelphia: Lippincott Williams & Wilkins 2004: 677-774.
Hoffman M: Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
Owen C: Historical account of tests of Hemostasis. Am J Clin Pathol 1990; 93(suppl 1): s3-s8.
Walenga JM: Molecular and automated assesments of coagulation. En: Corriveau DM, Fritsma GA: Hemostasis and thrombosis in the clinical laboratory. Philadelphia: Lippincott Company 1998: 367-416.
Izaguirre R, de Micheli A: En torno a la historia de las transfusiones sanguíneas. Rev Invest Clin 2002; 54: 552-558.
Cohn EJ: The separation of blood into fractions of therapeutic value. Ann Intern Med 1947; 26: 341-352.
Kekurck RA, Wolf P: A concentrate of human antihemophilic factor. Its use in six cases of haemophilia. Lancet 1957; 1: 647.
Pool JD, Shannon AE: Production of high-potency concentrates of antihemophilic globulin in a closed bag system. NEJM 1965; 273: 1443-1447.
Manno CS: The promise of third-generation recombinant therapy and gene therapy. Sem Hematol 2003; 40: s23-s28.
Roberts HR, Monroe DM, Hoffman M: Safety profile of recombinant factor VIIa. Sem Hematol 2004; 41: s101-s108.
Bernard GR, Vincent JL, Lattere PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
Larosa SP, Opal SM: Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005; 21: 433-448.
Kaiser B, Hoppendsteadt DH, Fareed J: Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 1998; 7: 1121-1137.
Simmonds R, Hermosa J, Rezende S: Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost 2001; 86: 374-385.
Falk E, Fuster V, Prediman S: Interrationship between atherosclerosis and thrombosis. En: Verstraete M, Fuster V, Topol E, Eds. Cardiovascular thombosis. Philadelphia: Lippincot Raven, 1998: 45-58.
Folsom A: Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86: 366-373.
Bick R, Hoppensteadt: Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects. A review and update. Clin Appl Thromb Hemost 2005; 11: 1-13.
O´Riordan MN, Higgins JR: Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17: 385-396.